Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Olivia Bobek

Showing results (1-10 of 5) with videos related to

Pageof 1
Sort By:
Journal of Geriatric Oncology|January 14, 2025
Association of age and performance status with adverse events in older adults with diffuse large B-cell lymphoma receiving frontline R-CHOP therapy: Alliance 151930, a secondary analysis of the phase III trial CALGB 50303Vicki A Morrison, Jennifer Le-Rademacher, Olivia Bobek, et al.
BJU International|May 12, 2026
Biochemical Recurrence Irradiation or Observation (BRIO) in patients with prostate cancer: protocol for a randomised control trialNancy Wei, Ryan M Phillips, Eugene Kwon, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 17, 2024
Clonal Hematopoiesis and Clinical Outcomes in Metastatic Castration-Resistant Prostate Cancer Patients Given Androgen Receptor Pathway Inhibitors (Alliance A031201)Jeffrey L Jensen, Olivia Bobek, Irenaeus C C Chan, et al.
Leukemia & Lymphoma|July 9, 2025
Ibrutinib added to standard conditioning and as maintenance therapy following autologous hematopoietic stem cell transplantation for relapsed or refractory activated-B-cell type Diffuse Large B-cell lymphoma: primary analysis of the US intergroup double-blind randomized phase III study Alliance A051301/BMT-CTN 1201Charalambos Andreadis, Olivia Bobek, Eric D Hsi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 30, 2023
Randomized Phase III Study of Enzalutamide Compared With Enzalutamide Plus Abiraterone for Metastatic Castration-Resistant Prostate Cancer (Alliance A031201 Trial)Michael J Morris, Glenn Heller, David W Hillman, et al.
Pageof 1

Showing results (1-10 of 5) with videos related to

Sort By:
Pageof 1
Journal of Geriatric Oncology|January 14, 2025
Association of age and performance status with adverse events in older adults with diffuse large B-cell lymphoma receiving frontline R-CHOP therapy: Alliance 151930, a secondary analysis of the phase III trial CALGB 50303Vicki A Morrison, Jennifer Le-Rademacher, Olivia Bobek, et al.
BJU International|May 12, 2026
Biochemical Recurrence Irradiation or Observation (BRIO) in patients with prostate cancer: protocol for a randomised control trialNancy Wei, Ryan M Phillips, Eugene Kwon, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 17, 2024
Clonal Hematopoiesis and Clinical Outcomes in Metastatic Castration-Resistant Prostate Cancer Patients Given Androgen Receptor Pathway Inhibitors (Alliance A031201)Jeffrey L Jensen, Olivia Bobek, Irenaeus C C Chan, et al.
Leukemia & Lymphoma|July 9, 2025
Ibrutinib added to standard conditioning and as maintenance therapy following autologous hematopoietic stem cell transplantation for relapsed or refractory activated-B-cell type Diffuse Large B-cell lymphoma: primary analysis of the US intergroup double-blind randomized phase III study Alliance A051301/BMT-CTN 1201Charalambos Andreadis, Olivia Bobek, Eric D Hsi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 30, 2023
Randomized Phase III Study of Enzalutamide Compared With Enzalutamide Plus Abiraterone for Metastatic Castration-Resistant Prostate Cancer (Alliance A031201 Trial)Michael J Morris, Glenn Heller, David W Hillman, et al.
Pageof 1